SELLAS Life Sciences Initiates Pediatric AML Patient Dosing in Phase 2 SLS009 Trial

SELLAS Life Sciences announced the first pediatric patient has been dosed in its ongoing Phase 2 trial of SLS009 (tambiciclib) for relapsed/refractory...
Home/KnloSights/Clinical Trial Updates/SELLAS Life Sciences Initiates Pediatric AML Patient Dosing in Phase 2 SLS009 Trial